take another look at a potential blookbuster
- Thread starter new redneck
- Start date
The page cannot be displayed
The page you are looking for is currently unavailable. The Web site might be experiencing technical difficulties, or you may need to adjust your browser settings.
To attempt fixing network connectivity problems, click Tools, and then click "Diagnose Connection Problems..."
Other options to try:
Click the Refresh button, or try again later.
If you typed the page address in the Address bar, make sure that it is spelled correctly.
To check your connection settings, click the Tools menu, and then click Internet Options. On the Connections tab, click Settings. The settings should match those provided by your local area network (LAN) administrator or Internet service provider (ISP).
See if your Internet connection settings are being detected. You can set Microsoft Windows to examine your network and automatically discover network connection settings (if your network administrator has enabled this setting).
Click the Tools menu, and then click Internet Options.
On the Connections tab, click LAN Settings.
Select Automatically detect settings, and then click OK.
Some sites require 128-bit connection security. Click the Help menu and then click About Internet Explorer to determine what strength security you have installed.
If you are trying to reach a secure site, make sure your Security settings can support it. Click the Tools menu, and then click Internet Options. On the Advanced tab, scroll to the Security section and check settings for SSL 2.0, SSL 3.0, TLS 1.0, PCT 1.0.
Click the Back button to try another link.
Cannot find server or DNS Error
Internet Explorer
WOrks for me :shrug: i'm drunk :sadwave: so well here it is :mj06:
Pfizer Takes the Plunge Into Stem-Cell Research
By Brian Orelli
November 14, 2008
Hey, Geron (Nasdaq: GERN) and StemCells (Nasdaq: STEM). Do you hear those footsteps? That's giant Pfizer (NYSE: PFE). It's off in the distance, but it's coming for you.
The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells. Small biotechs shouldn't be honing their slingshot skills to take down Goliath quite yet, though: It sounds like there might be gold falling out of the giant's pockets. Pfizer says the new unit will work on "several significant scientific collaborations."
Now may not be the perfect time to jump on the stem-cell bandwagon. It seems to me there are still a lot of details to be worked out before using stem cells as therapies. But Pfizer has to take this risk with the impending loss of Lipitor. GlaxoSmithKline (NYSE: GSK), which has also had rather stale growth lately, recently jumped in as well, announcing a partnership with the Harvard Stem Cell Institute.
Stem cells should make a more immediate impact as research tools to help drug development. In fact, pharmaceutical companies on both sides of the Atlantic, including Pfizer, Johnson & Johnson (NYSE: JNJ), and Sanofi-Aventis (NYSE: SNY), have joined forces to fund stem-cell initiatives as well as to help set up model systems to determine if drugs are safe before starting clinical trials.
But preventing side effects isn't exactly sexy, and it only has an indirect effect on the bottom line. Pfizer needs to get revenue growing -- especially after the inevitable drop when Lipitor faces generic competition -- and that's what this announcement is really about. When you're as big as Pfizer, you've got to plant a lot of beanstalks and hope that something grows into a blockbuster.
Pfizer Takes the Plunge Into Stem-Cell Research
By Brian Orelli
November 14, 2008
Hey, Geron (Nasdaq: GERN) and StemCells (Nasdaq: STEM). Do you hear those footsteps? That's giant Pfizer (NYSE: PFE). It's off in the distance, but it's coming for you.
The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells. Small biotechs shouldn't be honing their slingshot skills to take down Goliath quite yet, though: It sounds like there might be gold falling out of the giant's pockets. Pfizer says the new unit will work on "several significant scientific collaborations."
Now may not be the perfect time to jump on the stem-cell bandwagon. It seems to me there are still a lot of details to be worked out before using stem cells as therapies. But Pfizer has to take this risk with the impending loss of Lipitor. GlaxoSmithKline (NYSE: GSK), which has also had rather stale growth lately, recently jumped in as well, announcing a partnership with the Harvard Stem Cell Institute.
Stem cells should make a more immediate impact as research tools to help drug development. In fact, pharmaceutical companies on both sides of the Atlantic, including Pfizer, Johnson & Johnson (NYSE: JNJ), and Sanofi-Aventis (NYSE: SNY), have joined forces to fund stem-cell initiatives as well as to help set up model systems to determine if drugs are safe before starting clinical trials.
But preventing side effects isn't exactly sexy, and it only has an indirect effect on the bottom line. Pfizer needs to get revenue growing -- especially after the inevitable drop when Lipitor faces generic competition -- and that's what this announcement is really about. When you're as big as Pfizer, you've got to plant a lot of beanstalks and hope that something grows into a blockbuster.
